Trials / Not Yet Recruiting
Not Yet RecruitingNCT05017298
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
Clinical Study for Subjects With Coronavirus 2019 (COVID-19) Using Multiple Dose Intravenous Infusions of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Celltex Therapeutics Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Allogeneic adipose-derived stem cells | Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2024-11-01
- Completion
- 2026-11-15
- First posted
- 2021-08-23
- Last updated
- 2024-02-07
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05017298. Inclusion in this directory is not an endorsement.